Fröhli P, Graf C, Rhyner K
Schweiz Med Wochenschr. 1983 Nov 5;113(44):1622-7.
22 patients (13 with polycythaemia vera and 9 with primary thrombocythemia) were treated with 250 mg acetylsalicylic acid (ASA) daily for an average of 25 months. Before therapy was started, 3 patients had arterial thromboses, 3 had venous thromboses, 3 had spontaneous hemorrhage, 3 had acral circulatory disorders and 13 had dizziness, whereas under ASA treatment neither arterial nor venous thromboses occurred and only 4 mild spontaneous hemorrhages were recorded. Under ASA the circulatory disorders of the extremities disappeared completely in 11 patients and recurred intermittently in milder form in 2 patients. Dizziness was completely abolished in 12 of the 13 patients. Discontinuation of therapy was followed by prompt recurrence of symptoms. No correlation could be established between symptoms and extent of platelet disease either before or during ASA therapy. Low-dose salicylates are highly effective in the prevention and treatment of vascular complications in polycythaemia vera and primary thrombocythemia. Thanks to ASA, potentially leukemogenic cytostatic agents and radiophosphorus can be used more sparingly.
22例患者（13例真性红细胞增多症和9例原发性血小板增多症）接受每日250毫克阿司匹林（ASA）治疗，平均治疗25个月。在开始治疗前，3例患者发生动脉血栓形成，3例发生静脉血栓形成，3例发生自发性出血，3例有肢体循环障碍，13例有头晕症状；而在ASA治疗期间，未发生动脉或静脉血栓形成，仅记录到4例轻度自发性出血。在ASA治疗下，11例患者的肢体循环障碍完全消失，2例患者以较轻形式间歇性复发。13例患者中有12例头晕症状完全消失。停止治疗后症状迅速复发。在ASA治疗前或治疗期间，症状与血小板疾病的程度之间均未发现相关性。低剂量水杨酸盐在真性红细胞增多症和原发性血小板增多症的血管并发症预防和治疗中非常有效。由于使用了ASA，潜在致白血病的细胞毒性药物和放射性磷可以更谨慎地使用。
